Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013

Schernthaner, G., Currie, Craig J. and Schernthaner, G. H. 2013. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 36 (Supple) , S155-S161. 10.2337/dcS13-2031

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	American Diabetes Association
ISSN:	0149-5992
Last Modified:	01 Apr 2019 10:57
URI:	https://orca.cardiff.ac.uk/id/eprint/116758

Citation Data

Cited 70 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item